Autologous Anti-CD19 KIR-CAR-transduced T-cells SynKIR-310

**Semantic type:** Cell|Pharmacologic Substance

**Definition:** A preparation of autologous T-lymphocytes that have been genetically modified to express a killer cell immunoglobulin-like receptor (KIR)-based chimeric antigen receptor (CAR) consisting of an anti-CD19 single chain variable fragment (scFv) fused to the transmembrane and cytoplasmic domains of the stimulatory KIR 2DS2 (KIR2DS2), and the immunoreceptor tyrosine-based activation motif (ITAM)-containing adaptor protein and costimulatory chain DAP12, with potential immunomodulating and antineoplastic activities. Upon administration, the autologous anti-CD19 KIR-CAR-transduced T-cells SynKIR-310 specifically target and kill CD19-expressing tumor cells. CD19, a B-cell-specific cell surface antigen, is overexpressed in B-cell lineage malignancies and in certain B-cell-driven autoimmune diseases. KIR is normally expressed by natural killer (NK) cells, and KIR-based CAR may decrease T-cell exhaustion and enhance T-cell persistence.

**Synonyms:** - Autologous Anti-CD19 KIR-CAR-expressing T-cells SynKIR-310 - SynKIR 310 - SynKIR-310 - SynKIR310